According to the latest market report published by Credence Research, Inc. “Parkinson’s Disease Therapeutics Market – Growth, Future Prospects and Competitive Analysis, 2018 – 2026” the global Parkinson’s disease therapeutics market, was valued at US$ 2.41 Bn in 2017, and is expected to reach US$ 3.95 Bn by 2026 expanding at a CAGR of 5.6% from 2018 to 2026.
[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]
Parkinson’s disease is a type of progressive movement disorder characterized by muscle stiffness and tremor. The global market for Parkinson’s disease treatment will increase significantly over the forecast period, primarily due to the presence of late-stage medications such as APL-130277, Accordion Pill, P2B-001, ND0612H, etc. and the rising prevalence of the disease.
For the purpose of the study, the global market for Parkinson’s disease is classified on the basis of drug classes such as dopamine agonists, levodopa / carbidopa, anticholinergic medications, monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, and adenosine A2 receptor antagonist. Levodopa paired with carbidopa appears to be the standard treatment for Parkinson’s disease, which has a diminished impact on short-term use. Dopamine agonists are widely accepted for the treatment of PD used alone or in conjunction with levodopa / carbidopa.
At present, North America is leading the global market for PD Therapeutics, having a broader patient pool, benefiting from early diagnosis, expanding healthcare services and increasing the prevalence of PD. PD Therapeutic market in Asia-Pacific is expected to show lucrative growth over the forecast period due to increasing prevalence of PD and improving health infrastructure with evolving economic conditions.
Market Competition Assessment:
It is observed that, companies such as Abbvie, Inc., Biogen, Inc., Boehringer Ingelheim GmbH, F. Hoffman-La Roche, GlaxoSmithKline Plc., H. Lundbeck A/S, Impax Labs, Inc., Newron Pharmaceuticals SpA, Novartis AG, Orion Corporation, Teva Pharmaceutical Industries Ltd., UCB S.A. etc. are key players involved in R&D and manufacturing of PD therapeutics market.